Form 4: Director Jeffrey Jonas Receives Stock Options at COMPASS

Director Jeffrey M. Jonas was granted 21,110 stock options in COMPASS Pathways plc as part of a standard equity compensation award.

Summary

• Director Jeffrey M. Jonas received a grant of 21,110 share options on May 27, 2026.
• The options have an exercise price of $11.85 per share.
• The options vest in full on the earlier of the first anniversary of the grant date or the 2027 Annual General Meeting.
• The options expire on May 26, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market volatility affecting the value of the underlying shares relative to the $11.85 exercise price.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing solely on the equity compensation of a director.

Industry Context

StockSavvy.ai notes that equity grants to non-executive directors are standard practice in the biotechnology sector to incentivize long-term oversight and strategic alignment.

Comparison to Industry Standards

• The vesting schedule (one year or the next AGM) is consistent with standard corporate governance practices for director equity awards in the UK and US markets.
• The use of share options as a component of director compensation is common among mid-cap clinical-stage pharmaceutical companies.

Stakeholder Impact

• Minor potential dilution for shareholders upon the eventual exercise of the options.

Next Steps

• Vesting of options on May 27, 2027, or the 2027 Annual General Meeting.

Key Dates

Keywords

COMPASS Pathways, CMPS, Insider Trading, Stock Options, Director Compensation, Biotech